MTRF1L

Across TCGA pan-cancer cohorts, MTRF1L mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MTRF1L data layer compared with 29 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MTRF1L mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTRF1L expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LUAD, LSCC, and HNSC are the cancer types where MTRF1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.390	0.872	<.001	27	view →
LSCC	DFS	Median	All	0.682	0.890	.002	13	view →
HNSC	OS	Quartile	III,IV	0.549	0.909	.002	8	view →
CCRCC	OS	Median	II,III,IV	1.000	0.339	.007	6	view →
GBM	OS	Tertile	All	0.411	0.647	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MTRF1L–LUAD (DFS)

Open the LUAD breakdown →